1090 Horsham Road
About Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. develops, produces and markets ethical drugs, generic drugs, and fine chemicals for the pharmaceutical industry and disposable products for hospitals and home care services.
1527 articles with Teva Pharmaceuticals
TEVA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Teva Pharmaceutical Industries Limited To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Teva Pharmaceuticals Industries Limited.
The two generic drugmakers, along with many others, have been accused of conspiring to inflate the price of more than 100 generic drugs.
5/13/2019Gilead's Truvada is expected to lose patent protection in 2021, but a recent court decision in Europe could change that.
Teva Announces the Launch of a Generic Version of Delzicol® (mesalamine) Delayed-Release Capsules in the United States
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of Delzicol®1 (mesalamine) delayed-release capsules, 400 mg, in the U.S.
Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Tarceva®1 tablets, 100 and 150 mg, in the U.S.
Teva to Present New Long-Term Data on Efficacy and Safety of Fremanezumab at 2019 American Academy of Neurology Annual Meeting
Findings describe the efficacy and safety results of clinical trials of fremanezumab through 12 months of treatment in patients with chronic and episodic migraine
Spend base reduction of $2.5 billion since initiation of the restructuring plan in 2018; on-track to achieve $3.0 billion by the end of 2019
Teva Pharmaceutical Industries Ltd., announced the launch of a generic version of Letairis®1 Tablets, 5 mg and 10 mg, in the U.S.
Teva to Present New Central Nervous System Portfolio Data at 71st Annual Meeting of the American Academy of Neurology
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Company will present data at the 71st Annual Meeting of the American Academy of Neurology (AAN) in Philadelphia from May 4-10, 2019
Teva Pharmaceuticals recalled 35 lots of bulk Losartan Potassium after a known carcinogen was discovered in the active pharmaceutical ingredient.
Teva Pharmaceuticals USA, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply
Teva Pharmaceuticals USA, Inc. has initiated a voluntary recall in the United States, to the patient level, of 35 lots of bulk Losartan Potassium USP Tablets (6 lots of 25 mg strength and 29 lots of 100 mg strength).
Israel-based Teva Pharmaceuticals announced that it is halting the clinical development of fremanezumab (Ajovy) for cluster headaches. They based the decision on a pre-specified futility analysis of a Phase III clinical trial in episodic cluster headaches.
The FDA said the approval of Teva’s product is the first generic naloxone nasal spray for use in a community setting by individuals without medical training.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has entered into a new $2.3 billion unsecured revolving credit facility, which replaces its existing $3.0 billion credit facility.
xCella Biosciences announced a new antibody discovery research collaboration with Teva Pharmaceuticals Australia Pty Ltd. xCella will use its xPlorationTM single cell screening platform to identify rare antibodies against an undisclosed target of interest to Teva.
Teva to Host Conference Call to Discuss First Quarter 2019 Financial Results at 8 a.m. ET on May 2, 2019
Teva Pharmaceutical Industries Ltd. announced that it will issue a press release on its first quarter 2019 financial results on Thursday, May 2, 2019 at 7:00 a.m. ET.
Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults
In clinical trials, many patients on AJOVY experienced significant reductions of at least 50% in the number of monthly migraine days with reduction observed as early as week one
Teva Pharmaceutical Industries Ltd. announced that a three-member panel of the European Patent Office’s Opposition Division upheld patent EP 2 949 335 covering Teva’s COPAXONE® 40mg product in Europe.
Teva Announces Launch of a Generic Version of EXJADE® (deferasirox) Tablets For Oral Suspension in the United States
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of EXJADE®1 (deferasirox) Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, in the U.S.
Genedata Biologics® streamlines Teva’s R&D workflows and increases operational efficiency